Greenstone launches authorized generic of Aromasin
PEAPACK, N.J. — Greenstone has introduced an authorized generic treatment for breast cancer, the generics subsidiary of Pfizer said.
The company announced the launch of exemestane tablets, an authorized generic version of Pfizer’s Aromasin. Aromasin is used to treat early breast cancer in menopausal women who already have taken the drug tamoxifen for two to three years, as well as breast cancer in women whose disease has worsened while taking tamoxifen, which is widely available as a generic.
Authorized generics are branded drugs sold under their generic names at a reduced price.
Novartis’ Afinitor approved as advanced pancreatic NET treatment
EAST HANOVER, N.J. — The Food and Drug Administration has approved a drug made by Novartis as the first treatment for advanced pancreatic neuroendocrine tumors, Novartis said Thursday.
Novartis announced the approval of Afinitor (everolimus), saying it marked the first approval of a drug for advanced pancreatic NET in nearly 30 years. The drug already is approved for treating cancers of the kidneys and brain.
“The FDA approval of Afinitor represents an important step forward for patients with advanced pancreatic NET,” medicine professor James Yao of the University of Texas M.D. Anderson Cancer Center in Houston said on behalf of Novartis. “Patients will now have access to a treatment that has been shown to significantly delay tumor growth and reduce the risk of disease progression.”
Lilly invests $2.5 million into Grow What Works campaign
INDIANAPOLIS — Eli Lilly announced its largest-ever education-focused grant.
The drug maker has teamed up with nonprofit group The Mind Trust to launch the Grow What Works campaign, which seeks to raise and invest $18 million in the highest-impact education organizations working in Indianapolis. Lilly invested $2.5 million for the cause.
Since its founding in 2006, The Mind Trust has been strategically building a network of the nation’s best education reform organizations in Indianapolis, Lilly said.
"We believe that providing access to an excellent education for all of our children is the key to our city’s future," Lilly chairman, president and CEO John Lechleiter said. "Lilly has been impressed with the work of The Mind Trust. It has amassed an impressive record of making strategic investments and has become a recognized model for leading education reform. We’re honored to invest in the Grow What Works campaign, and we encourage other organizations to do the same. The Mind Trust is uniquely positioned to be an effective catalyst for education reform in Indianapolis."